These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A; Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085 [TBL] [Abstract][Full Text] [Related]
26. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. Martelli L; Peyrin-Biroulet L Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715 [TBL] [Abstract][Full Text] [Related]
27. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. Meijboom RW; Gardarsdottir H; Egberts TCG; Giezen TJ BioDrugs; 2022 Jan; 36(1):27-39. PubMed ID: 34870802 [TBL] [Abstract][Full Text] [Related]
28. Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study. Belleudi V; Rosa AC; Poggi FR; Armuzzi A; Nicastri E; Goletti D; Diamanti AP; Davoli M; Agabiti N; Addis A J Clin Med; 2021 May; 10(11):. PubMed ID: 34071452 [TBL] [Abstract][Full Text] [Related]
29. Analysis of biosimilars consumption in an Italian Local Health Authority. Ferrara F; Capuozzo M; Langella R; Trama U; Nava E; Ottaiano A; Zovi A Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5317-5323. PubMed ID: 38231416 [TBL] [Abstract][Full Text] [Related]
30. Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico. Mayoral-Zavala A; Esquivel-Aguilar A; Del Real-Calzada CM; Gutiérrez-Grobe Y; Ramos-García J; Rocha-Ramírez JL; Rojas-Illanes MF; Rubio-Martínez B; Sánchez-Chávez X; Yamamoto-Furusho JK; Rev Gastroenterol Mex (Engl Ed); 2018; 83(4):414-423. PubMed ID: 29685744 [TBL] [Abstract][Full Text] [Related]
31. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. Radin M; Sciascia S; Roccatello D; Cuadrado MJ BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633 [TBL] [Abstract][Full Text] [Related]
32. Bioequivalence studies with anti-TNF biosimilars. Gimeno-Gracia M; Gargallo-Puyuelo CJ; Gomollón F Expert Opin Biol Ther; 2019 Oct; 19(10):1031-1043. PubMed ID: 30574813 [No Abstract] [Full Text] [Related]
33. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness. Dutcher SK; Fazio-Eynullayeva E; Eworuke E; Carruth A; Dee EC; Blum MD; Nguyen MD; Toh S; Panozzo CA; Lyons JG Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):786-795. PubMed ID: 31828887 [TBL] [Abstract][Full Text] [Related]
34. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341 [TBL] [Abstract][Full Text] [Related]
35. Biosimilars in Dermatology - theory becomes reality. Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594 [TBL] [Abstract][Full Text] [Related]
36. Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy. Lucchesi S; Marcianò I; Panagia P; Intelisano R; Randazzo MP; Sgroi C; Altavilla G; Santarpia M; Adamo V; Franchina T; Ferraù F; Reitano P; Trifirò G Clin Drug Investig; 2018 Mar; 38(3):269-278. PubMed ID: 29076054 [TBL] [Abstract][Full Text] [Related]
37. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. Sagami S; Nishikawa K; Yamada F; Suzuki Y; Watanabe M; Hibi T J Gastroenterol Hepatol; 2021 Aug; 36(8):2091-2100. PubMed ID: 33450057 [TBL] [Abstract][Full Text] [Related]
38. The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company. Ferrara F; Capuozzo M; Langella R; Trama U; Nava E; Zovi A J Cancer Policy; 2024 Jun; 40():100473. PubMed ID: 38508413 [TBL] [Abstract][Full Text] [Related]
39. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database. Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324 [TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis. Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]